Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
72,314,703
-
Share change
-
+8,118,938
-
Total reported value
-
$3,517,677,257
-
Put/Call ratio
-
63%
-
Price per share
-
$48.64
-
Number of holders
-
426
-
Value change
-
+$428,897,787
-
Number of buys
-
218
-
Number of sells
-
159
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2025
As of 30 Jun 2025,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
426 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,314,703 shares.
The largest 10 holders included
ARK Investment Management LLC, BlackRock, Inc., Capital International Investors, T. Rowe Price Investment Management, Inc., STATE STREET CORP, UBS Group AG, Orbis Allan Gray Ltd, Sumitomo Mitsui Trust Group, Inc., Nikko Asset Management Americas, Inc., and VANGUARD GROUP INC.
This page lists
426
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.